In a regulatory filing, BioMarin chief legal officer George Eric Davis disclosed the sale of 13,764 common shares of the company on December 13 at a price of $95.30 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMRN:
- BioMarin granted orphan status for antitrypsin deficiency treatment
- BioMarin closes reimbursement agreement with German insurance fund for Roctavian
- Block upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- BioMarin initiated with an Overweight at Wells Fargo
- Biotech Alert: Searches spiking for these stocks today